History of ectonucleotidases and their role in purinergic signaling.
5'-Nucleotidase
/ chemistry
Adenosine Triphosphate
/ metabolism
Animals
Crystallization
/ methods
Humans
Protein Structure, Secondary
Purinergic Agonists
/ administration & dosage
Purinergic Antagonists
/ administration & dosage
Receptors, Purinergic
/ metabolism
Signal Transduction
/ drug effects
Tissue Distribution
/ drug effects
Alkaline phosphatase
Ecto-5′-nucleotidase
Ecto-nucleotide pyrophosphatase/phosphodiesterase
Ectonucleotidase
History
Nucleoside triphosphate diphosphohydrolase
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
29
09
2020
revised:
03
11
2020
accepted:
03
11
2020
pubmed:
9
11
2020
medline:
15
9
2021
entrez:
8
11
2020
Statut:
ppublish
Résumé
Ectonucleotidases are key for purinergic signaling. They control the duration of activity of purinergic receptor agonists. At the same time, they produce hydrolysis products as additional ligands of purinergic receptors. Due to the considerable diversity of enzymes, purinergic receptor ligands and purinergic receptors, deciphering the impact of extracellular purinergic receptor control has become a challenge. The first group of enzymes described were the alkaline phosphatases - at the time not as nucleotide-metabolizing but as nonspecific phosphatases. Enzymes now referred to as nucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase were the first and only nucleotide-specific ectonucleotidases identified. And they were the first group of enzymes related to purinergic signaling. Additional research brought to light a surprising number of ectoenzymes with broad substrate specificity, which can also hydrolyze nucleotides. This short overview traces the development of the field and briefly highlights important results and benefits for therapies of human diseases achieved within nearly a century of investigations.
Identifiants
pubmed: 33161020
pii: S0006-2952(20)30558-X
doi: 10.1016/j.bcp.2020.114322
pii:
doi:
Substances chimiques
Purinergic Agonists
0
Purinergic Antagonists
0
Receptors, Purinergic
0
Adenosine Triphosphate
8L70Q75FXE
5'-Nucleotidase
EC 3.1.3.5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114322Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.